Empirical tuberculosis treatment or improved diagnostics?

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 2, 2012, Pages 280-

  Manabe, Yukari C ^a   Worodria, William ^a   Cobelens, Frank ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

BODY MASS; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; GABON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; LETTER; MORTALITY; MOZAMBIQUE; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS; UGANDA;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 84855707387     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0242     Document Type: Letter

References (2)

1. Lawn S D, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 2011; 15: 287-295.
2. Manabe Y C, Breen R, Perti T, Girardi E, Sterling T. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after antiretroviral therapy initiation. J Infect Dis 2009; 199: 437-444.